Shop- All categories
- Skin boosters
- Jalupro
Juvelook 1x50 mg
Juvelook 1x50 mg
In stock
In stock
£ 135.00
Juvelook 1x50 mg is a PDLLA and hyaluronic acid injectable developed for practitioners seeking a collagen-stimulating approach to facial rejuvenation. Unlike a conventional cross-linked hyaluronic acid dermal filler, Juvelook combines two distinct components within a single formulation: poly-D,L-lactic acid (PDLLA) and hyaluronic acid (HA). This combination is why Juvelook is frequently described within the aesthetic medicine market as a hybrid collagen biostimulator or hybrid skin booster.
The 50 mg presentation contains 42.5 mg of PDLLA and 7.5 mg of HA, corresponding to an 85:15 PDLLA-to-HA composition. The product is supplied as a lyophilised powder, and the manufacturer's product information identifies PDLLA and HA as its principal components.
From an aesthetic perspective, the combination is intended to address more than simple hydration. Hyaluronic acid is naturally present within the extracellular matrix and has a well-established role in maintaining water content and tissue hydration. Within an injectable aesthetic formulation, HA can contribute to improved skin hydration and a more supple appearance. PDLLA, meanwhile, is a biodegradable polymer used in aesthetic medicine for its collagen-stimulating properties. Juvelook's manufacturer describes its PDLLA as having a porous, reticular structure, developed using VAIM's patented manufacturing technology.
For aesthetic clinics, this makes Juvelook particularly relevant to treatment strategies focused on skin quality, fine lines, textural irregularities and signs of skin ageing. Rather than positioning the product solely as a volumising filler, practitioners can consider its role within a broader facial rejuvenation programme designed to support progressive improvements in the appearance and quality of the skin.
The product's relatively small PDLLA particle size is another important characteristic. Available product information reports particles in the region of 20–40 μm for the 50 mg formulation. The manufacturer describes Juvelook as a product used for the physical restoration of adult facial wrinkles through subcutaneous administration.
For clinics, Juvelook may therefore complement other aesthetic procedures where the primary objective is not aggressive structural augmentation but a more regenerative-looking, natural skin rejuvenation outcome. Depending on the patient's anatomy, skin condition and clinical objectives, practitioners may consider areas such as the cheeks, perioral region, lower face and other areas demonstrating fine lines, reduced elasticity or compromised skin quality. Treatment selection and injection technique should always follow the manufacturer's current instructions for use and the practitioner's professional assessment.
One of the key reasons PDLLA skin boosters and collagen biostimulators have become increasingly relevant in aesthetic medicine is the growing demand for subtle, progressive results. Many patients prefer improvements in skin quality rather than an obviously augmented appearance. A product such as Juvelook can therefore form part of a personalised skin rejuvenation protocol, particularly for patients presenting with early to moderate signs of ageing and reduced dermal quality.
Juvelook is also distinct from Juvelook Volume, another product within the Juvelook range. The manufacturer's information lists the standard 50 mg Juvelook formulation at 42.5 mg PDLLA + 7.5 mg HA, while Juvelook Volume contains a substantially higher total formulation of 200 mg, comprising 170 mg PDLLA and 30 mg HA. This distinction is important when selecting the appropriate product for a patient's treatment objectives.
For professional clinics, product selection should always be based on patient assessment, treatment area, tissue characteristics, desired clinical outcome and the manufacturer's approved indications and instructions. Juvelook should not be considered interchangeable with traditional HA dermal fillers, PLLA products or other injectable biostimulators simply because they may share overlapping aesthetic applications.
As with all injectable aesthetic products, practitioners should review the current Instructions for Use (IFU), contraindications, warnings, preparation requirements and recommended administration technique before treatment. Appropriate patient selection, aseptic technique and a thorough understanding of facial anatomy remain essential components of safe aesthetic practice.
Overall, Juvelook 1x50 mg provides aesthetic practitioners with a PDLLA + HA injectable platform designed around the combination of collagen stimulation and HA-associated hydration. Its formulation makes it particularly relevant to clinics developing treatment protocols for facial rejuvenation, fine lines, skin laxity and overall improvement in skin quality.
Treatment Areas
Depending on the indication, patient assessment and applicable product instructions, Juvelook may be considered for professional treatment of:
- Face
- Cheeks
- Mid-face
- Lower face
- Perioral region
- Fine facial lines and wrinkles
- Areas of reduced skin elasticity
- Areas where improved skin quality and hydration are clinically desired
The manufacturer's stated use relates to improving the appearance of adult facial wrinkles through physical restoration. Specific treatment areas, injection depth and technique should be determined according to the current IFU and the practitioner's clinical assessment.
Usage
Juvelook 1x50 mg is supplied as a lyophilised powder for professional preparation prior to administration. The product should only be prepared and administered by appropriately qualified healthcare professionals who have received suitable training in injectable aesthetic procedures.
The manufacturer's current instructions for use should always be followed for reconstitution, preparation, injection technique, treatment depth, dosage, storage and post-treatment management. These parameters should not be substituted with protocols from other PDLLA or dermal-filler products.
Treatment planning should take into consideration the patient's facial anatomy, skin condition, degree of ageing, previous aesthetic procedures and desired outcome. A personalised treatment programme may be required to achieve the intended clinical result.
Ingredient ListPoly-D,L-Lactic Acid (PDLLA) – 42.5 mg
PDLLA is a biodegradable polymer used in aesthetic medicine as a collagen-stimulating material. Juvelook's manufacturer describes its PDLLA as having a porous reticular structure developed using VAIM's proprietary technology. The component is intended to support longer-term skin rejuvenation through collagen stimulation.
Hyaluronic Acid (HA) – 7.5 mg
Hyaluronic acid is a naturally occurring polysaccharide with strong water-binding properties. Within Juvelook, HA complements PDLLA by contributing to hydration and an immediate improvement in skin appearance. The manufacturer's 50 mg formulation contains 7.5 mg HA.
Total formulation
50 mg per vial: 42.5 mg PDLLA + 7.5 mg HA
Product Dimensions / Size
1 vial × 50 mg
The product is supplied as a lyophilised powder. The 50 mg formulation contains 42.5 mg PDLLA and 7.5 mg HA, with reported PDLLA particle size of approximately 20–40 μm.
Product Duration
The duration of aesthetic improvement can vary according to the patient's age, skin condition, treatment plan, injection technique, lifestyle and individual biological response.
Some professional product information reports an effect lasting approximately 12–18 months, but this should be regarded as an indicative treatment duration rather than a guarantee for every patient.
Manufactured By
VAIM Co., Ltd. (VAIM Global), South Korea
The official Juvelook manufacturer information identifies VAIM Co., Ltd. as the company behind the Juvelook technology and product range.
Frequently Asked Questions1. What is Juvelook 1x50 mg?
Juvelook 1x50 mg is an injectable aesthetic product combining PDLLA (poly-D,L-lactic acid) and hyaluronic acid (HA). The 50 mg formulation contains 42.5 mg PDLLA and 7.5 mg HA. It is designed for professional aesthetic use and is intended to support facial wrinkle improvement and skin rejuvenation.
2. What is the difference between Juvelook and a traditional dermal filler?
Traditional HA dermal fillers are primarily designed to provide structural volume and contouring. Juvelook combines PDLLA with HA and is positioned around collagen stimulation and skin quality, rather than conventional high-volume augmentation. It should therefore be selected according to the patient's clinical indication rather than treated as a direct replacement for a conventional filler.
3. What areas can Juvelook be used to treat?
Juvelook is associated with facial rejuvenation and can be considered for areas affected by fine lines, reduced elasticity and changes in skin quality. Potential facial treatment areas include the cheeks, mid-face, lower face and perioral region, subject to the product's current IFU, indication and practitioner assessment.
4. How long does Juvelook last?
The duration varies between patients and depends on factors including treatment protocol, skin condition, age and individual response. Some professional product information reports approximately 12–18 months, although this should not be interpreted as a guaranteed duration for every patient.
5. What are the main ingredients in Juvelook 50 mg?
The principal ingredients are PDLLA and hyaluronic acid. Each 50 mg vial contains 42.5 mg PDLLA and 7.5 mg HA. PDLLA provides the collagen-stimulating component, while HA contributes hydration and supports the immediate aesthetic component of the treatment.
Quantity
1
Insurance for Juvelook 1x50 mg
Compare insurance quotes from trusted partners.
Get your quote
Meet your seller
Skin On You
5.0 (16,905)
255 products
6,107 sold
We’re an MHRA licensed broker.All-in-one platform for aesthetic clinics. Manage bookings and digital consent easily. Reduce paperwork and save time. Secure client data and records. Built for modern practitioners.
Get in touch
